title: FDA advisory decision highlights some problems inherent in pragmatic trials.
authors: Mike
authors: M
authors: Mitka
mesh_terms: D026683:Advisory Committees; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D000069552:Rivaroxaban; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D009025:Morpholines; D013876:Thiophenes; D014859:Warfarin; D000069552:Rivaroxaban